Bluejay's lead product candidate brelovitug (BJT-778) recently received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD).

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

The viral illness kills more people in the city than HIV, but antiviral medications may be helping cut its transmission.

The Philadelphia Department of Public Health has released its 2023 Annual Report on Hepatitis B, C, and D in the city. The ...

Megyn Kelly is joined by Turning Point USA's Charlie Kirk, host of The Charlie Kirk Show, to talk about RFK Jr. getting ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

If you’d like to attend this special live town hall ... “Some of the things he said were just not true. For example, for hepatitis B vaccines there’s no safety trials. I have actually performed ...

Robert F. Kennedy Jr. said he wanted "gold standard science" on vaccines, but when presented with compelling research, he ...

Robert F. Kennedy Jr.'s nomination for HHS secretary may be in jeopardy after Sen. Bill Cassidy, MD (R-La.), said he was ...

If you come out unequivocally — ‘vaccines are safe, it does not cause autism’ that would have an incredible impact,” Sen.

Kennedy’s bid to serve as America’s top health official may be decided by a handful of Republicans, including several ...